DEA Greenlights Weed Imports for Natural Products Research Lab
Published Date: 12/22/2025
Notice
Summary
The National Center for Natural Products Research wants to become an official importer of certain controlled substances, including marijuana. People and companies involved can share their thoughts or ask for a hearing by January 21, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
University Seeks Importer Registration
On September 8, 2025, the National Center for Natural Products Research applied to be registered to import marihuana (drug code 7360, Schedule I) and tetrahydrocannabinols (drug code 7370, Schedule I) for research and manufacturing. The application says the center plans to acquire new genetic materials with different cannabinoid profiles for research and manufacturing purposes.
Import Approval Excludes Finished Drugs
The DEA notice says any authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. The registration is limited to the activities authorized under 21 U.S.C. 952(a)(2).
Stakeholders Can Comment by Jan 21, 2026
Registered bulk manufacturers of the affected drug classes and other applicants may submit electronic comments or objections through regulations.gov, or request a hearing, on or before January 21, 2026. Hearing requests must also be mailed to the DEA hearing clerk at the Springfield, Virginia addresses listed in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-23502 — Texas Eastern Transmission, L.P.; Notice of Scoping Period Requesting Comments on Environmental Issues for the Proposed Kosciusko Compressor Station Replacement Project
Texas Eastern Transmission wants to replace a compressor station in Attala County, Mississippi, and the government is asking the public for their thoughts on how this might affect the environment. If you live nearby or care about nature, now’s the time to speak up before January 15, 2026. This project could change local air and land conditions, so your input helps decide if it moves forward safely and smartly.
Next: 2025-23504 — Agency Information Collection Activities: Program Analysis and Evaluation (PA&E) Office, Stakeholder Engagement Division (SED) Convenings Evaluation
The Cybersecurity and Infrastructure Security Agency (CISA) wants your thoughts on a new survey to see how well their meetings with partners are working. This helps them improve how they gather feedback and make decisions. If you’re involved or interested, you’ve got until January 21, 2026, to share your ideas—no cost, just a few minutes of your time!